A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

The purpose of this clinical study is to learn about safety and effects of berobenatide(PF‐08653944) in adults with obesity disease, a condition where a person has too muchbody fat, which can harm their health and increase the risk of other medical problems.Some people in this study may also have type 2 diabetes, a condition in which the bodydoes not use insulin properly, causing blood sugar levels to become too high.This study is seeking participants in Japan who: ‐ Have obesity disease. ‐ May have type 2 diabetes. ‐ Meet the study‐specific age, weight and health requirements.About 180 adults will take part in this study. Participants will be randomly assigned toreceive either berobenatide or a placebo. A placebo looks like the study medicine butdoes not contain any active medicine.Berobenatide or placebo will be given as an injection under the skin of the abdomen(belly area). The study will compare the experiences of people receiving berobenatidewith those receiving placebo to determine whether berobenatide can help people loseweight. The study will also assess the safety of berobenatide and its effects on bodyweight and other health measures.People will take part in this study for about 22 months. During this time, they will haveabout 15 study visits at the site. They will also have 2 study visits over the phone.